이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Kiniksa Pharmaceuticals International 관리
관리 기준 확인 4/4
Kiniksa Pharmaceuticals International's CEO는 Sanj Patel, Jul2015 에 임명되었습니다 의 임기는 9.08 년입니다. 총 연간 보상은 $ 5.30M, 16.3% 로 구성됩니다. 16.3% 급여 및 83.7% 보너스(회사 주식 및 옵션 포함). 는 $ 45.19M 가치에 해당하는 회사 주식의 2.38% 직접 소유합니다. 45.19M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 7.7 년입니다.
주요 정보
Sanj Patel
최고 경영자
US$5.3m
총 보상
| CEO 급여 비율 | 16.3% |
| CEO 임기 | 9.3yrs |
| CEO 소유권 | 2.4% |
| 경영진 평균 재임 기간 | 3.8yrs |
| 이사회 평균 재임 기간 | 7.8yrs |
최근 관리 업데이트
Recent updates
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
보상 대 시장: Sanj 의 총 보상 ($USD 5.30M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.67M ).
보상과 수익: Sanj 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Sanj Patel (55 yo)
9.3yrs
테뉴어
US$5,297,067
보상
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.41% $ 41.7m | |
| Senior VP & COO | 2.8yrs | US$1.75m | 0.16% $ 2.8m | |
| Senior VP & Chief Medical Officer | 8.2yrs | US$1.79m | 0.073% $ 1.3m | |
| Senior VP & CFO | 3.8yrs | 데이터 없음 | 0.032% $ 557.6k | |
| Chief Accounting Officer & Group VP of Finance | 4.7yrs | 데이터 없음 | 0.037% $ 642.2k | |
| Senior Vice President of Technical Operations | 3.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Compliance Officer | 3.5yrs | 데이터 없음 | 데이터 없음 | |
| SVP, General Counsel & Secretary | 3.8yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Corporate Affairs | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | 3.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Commercial Officer | 2.8yrs | 데이터 없음 | 0.031% $ 528.0k | |
| Chief Business Officer | less than a year | 데이터 없음 | 데이터 없음 |
3.8yrs
평균 재임 기간
51.5yo
평균 연령
경험이 풍부한 관리: KNSA 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.41% $ 41.7m | |
| Independent Director | 6.7yrs | US$362.66k | 0.013% $ 227.7k | |
| Lead Independent Director | 9yrs | US$411.06k | 0.028% $ 481.9k | |
| Independent Director | 7.8yrs | US$380.36k | 0.013% $ 227.7k | |
| Independent Director | 9yrs | US$372.55k | 0.013% $ 227.7k | |
| Independent Director | 5.6yrs | US$459.75k | 0.018% $ 313.2k | |
| Independent Director | 4.3yrs | US$365.36k | 0.013% $ 227.7k | |
| Independent Director | 9yrs | US$371.96k | 0.0070% $ 121.5k | |
| Chairman of Scientific Advisory Board | no data | 데이터 없음 | 2.08% $ 35.9m | |
| Independent Director | 6.7yrs | US$365.36k | 0.013% $ 227.7k |
7.8yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 이사회: KNSA 의 이사회는 경험(평균 재직 기간 7.5 년)으로 간주됩니다.